Bertolt Kreft

Company: Bright Peak Therapeutics

Job title: Chief Scientific Officer

Seminars:

Exploring how BPT567 (PD1-IL18) Induces Potent Anti-tumor Immune Responses 12:10 pm - 12:30 pm

Revealing BPT567 as an immunoconjugate (IC) consisting of an IL-18 binding protein-resistant IL-18 payload that is chemically conjugated to a PD-1-blocking antibody Triggering a profound expansion of intratumoral PD1+ CD8+ T effector memory cells accompanied by a high local induction of IFNg release within the tumor microenvironment.  Outlining BPT567 exhibiting a strong anti-tumor efficacy at…Read more

day: Conference Day One